Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of patients with BPDCN who recieved HSCT following induction with tagraxofusp

Naveen Pemmaraju • 9 Feb 2021
TCT 2021
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy with traditionally poor patient outcomes. In this video, Naveen Pemmaraju, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the outcomes of adult patients with BPDCN who received hematopoietic stem cell transplantation (HSCT) following remission induction with tagraxofusp, a targeted therapy directed to CD123. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Naveen Pemmaraju

1:40
TAG-AZA-VEN in the treatment of patients with newly diagnosed CD123+ AML
Naveen Pemmaraju • 11 Dec 2023
1:29
Exciting developments in the field of BPDCN
Naveen Pemmaraju • 11 Dec 2023
1:58
TRANSFORM-1: navitoclax + ruxolitinib vs placebo + ruxolitinib in patients with untreated MF
Naveen Pemmaraju • 11 Dec 2023
1:15
Exploring the evolving treatment landscape of myelofibrosis
Naveen Pemmaraju • 3 Jun 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals